Vessel size and perfusion-derived vascular habitat refines prediction of treatment failure to bevacizumab in recurrent glioblastomas: validation in a prospective cohort
Authors:
- 15 October 2022
- journal article
- research article
- Published by Springer Nature in European Radiology
- Vol. 33 (6) , 4475-4485
Abstract
Objectives Anti-angiogenic therapy may not benefit all patients with recurrent glioblastomas, and imaging biomarker predicting treatment response to anti-angiogenic therapy is currently limited. We aimed to develop and validate vascular habitats based on perfusion and vessel size to predict time to progression (TTP) in patients with recurrent glioblastomas treated with bevacizumab. Methods Sixty-nine patients with recurrent glioblastomas treated with bevacizumab who underwent pretreatment MRI with dynamic susceptibility contrast imaging and vessel architectural imaging were enrolled. Vascular habitats were constructed using vessel size index (VSI) and relative cerebral blood volume (rCBV). Associations with vascular habitats and TTP were analyzed using Cox proportional hazard regression analysis. In a prospectively enrolled validation cohort consisting of 15 patients (ClinicalTrials.gov identifier; NCT04143425), stratification of TTP was demonstrated by the Kaplan-Meier method (log-rank test) using vascular habitats. Results Three vascular habitats consisting of high, intermediate, and low angiogenic habitats were identified with rCBV and VSI. Both high angiogenic and intermediate angiogenic habitats were significantly associated with a shorter TTP (hazard ratio [HR], 2.78 and 1.82, respectively; largest p = .003) and so was rCBV (HR, 2.15; p = .02). Concordance probability index of vascular habitat combining high and intermediate angiogenic habitats was 0.74. Vascular habitats stratified patients as good or poor responder in a prospective cohort (p = .059). Conclusions Perfusion- and vessel size-derived vascular habitats predicted TTP in recurrent glioblastomas treated with anti-angiogenic therapy and aided patient stratification in a prospective validation cohort. Trial registration ClinicalTrials.gov identifier: NCT04143425 Key Points • High and intermediate angiogenic habitats predicted TTP in recurrent glioblastomas treated with anti-angiogenic therapy. • Vascular habitats combining high and intermediate angiogenic habitats aided patient stratification for anti-angiogenic therapy in recurrent glioblastomas.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2020R1A2B5B01001707)
- National Research Foundation of Korea (NRF-2020R1A2C4001748)
This publication has 26 references indexed in Scilit:
- Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapyNature Medicine, 2013
- Vessel co‐option in primary human tumors and metastases: an obstacle to effective anti‐angiogenic treatment?Cancer Medicine, 2013
- Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood PerfusionCancer Research, 2012
- Normalization of the Vasculature for Treatment of Cancer and Other DiseasesPhysiological Reviews, 2011
- Targeting hypoxia in cancer therapyNature Reviews Cancer, 2011
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumabNeuro-Oncology, 2010
- The shunt problem: control of functional shunting in normal and tumour vasculatureNature Reviews Cancer, 2010
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma PatientsCancer Research, 2009